Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens (original) (raw)

Antimicrobial Agents and Chemotherapy, 2016

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis

Journal of Antimicrobial Chemotherapy, 2013

To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B

Ruchika Nandha

Indian Journal of Critical Care Medicine, 2013

View PDFchevron_right

Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity

Maria Helena Rigatto

Antibiotics

View PDFchevron_right

Nephrotoxicity Associated with Intravenous Polymyxin B Once versus Twice Daily Dosing Regimen

Daniel Eiras

Antimicrobial agents and chemotherapy, 2018

View PDFchevron_right

Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B

Maria Helena Rigatto

Antimicrobial agents and chemotherapy, 2017

View PDFchevron_right

Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study

Maria Helena Rigatto

Journal of Antimicrobial Chemotherapy, 2015

View PDFchevron_right

Parenteral polymyxins: Assessing efficacy and safety in critically ill patients with renal dysfunction

Ruchika Nandha

Indian Journal of Pharmacology, 2013

View PDFchevron_right

Prevalence and Risk Factors for Acute Kidney Injury Associated with Parenteral Polymyxin B Use

Carlos Mendes

Annals of Pharmacotherapy, 2009

View PDFchevron_right

Comparative Pharmacokinetic Profiling of Different Polymyxin B Components

Pooja Manchandani

View PDFchevron_right

Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures

Andrea Kwa

Microorganisms, 2020

View PDFchevron_right

Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?

Phillip Bergen

Diagnostic Microbiology and Infectious Disease, 2012

View PDFchevron_right

Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use

Alan Forrest, Zackery Bulman

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015

View PDFchevron_right

Therapeutic Specification of the Last Resort Polymyxins: An Intelligent Approach

jahidul hasan

International Journal of Infection

View PDFchevron_right

Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model

Pooja Manchandani, Jian Zhou

View PDFchevron_right

Polymyxins Nebulization over Intravenous Injection: Pharmacokinetics and Pharmacodynamics-Based Therapeutic Evaluation

jahidul hasan

Journal of Pharmaceutical Research International

View PDFchevron_right

Global survey of polymyxin use: A call for international guidelines

Heiman Wertheim

Journal of Global Antimicrobial Resistance, 2013

View PDFchevron_right

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens

Phillip Bergen

Frontiers in Pharmacology, 2022

View PDFchevron_right

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infecti...

ilias Karaiskos

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

View PDFchevron_right

Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients

Elizabeth Daher

Pathogens and global health, 2017

View PDFchevron_right

Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society

Phillip Bergen

Journal of Zhejiang University-SCIENCE B

View PDFchevron_right

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

David Paterson

The Lancet Infectious Diseases, 2015

View PDFchevron_right

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm

Cornelia Landersdorfer

Antimicrobial agents and chemotherapy, 2018

View PDFchevron_right

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity

Gladys Prado

Diagnostic Microbiology and Infectious Disease, 2009

View PDFchevron_right

Polymyxin B in combination with in vitro non-susceptible antimicrobials versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections

Maria Helena Rigatto

Antimicrobial Agents and Chemotherapy, 2015

View PDFchevron_right

Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity

Pooja Manchandani

View PDFchevron_right

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Andrea Kwa

Case reports in infectious diseases, 2014

View PDFchevron_right

A Study on Polymyxin B Induced Nephrotoxicity: A Systematic Review

Samhitha Chetty

International Journal of Pharmaceutical Sciences Review and Research, 2022

View PDFchevron_right

Evaluation of susceptibility testing methods for polymyxin

babita gupta

International Journal of Infectious Diseases, 2010

View PDFchevron_right

Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens (original) (raw)

Related papers